Expression of miRNAs in papillary thyroid carcinomas is associated with BRAF mutation and clinicopathological features in Chinese patients

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Sun, Yun ^a   Yu, Shuang ^a   Liu, Yuanyuan ^a   Wang, Fen ^a   Liu, Yujie ^a   Xiao, Haipeng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MICRORNA; MICRORNA 146B; MICRORNA 181; MICRORNA 21; MICRORNA 221; MICRORNA 222; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BENIGN TUMOR; BRAF GENE; CANCER STAGING; CERVICAL LYMPH NODE; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID NODULE; TUMOR DIFFERENTIATION;

EID: 84877262781     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/128735     Document Type: Article

References (42)

1. Sipos J. A., Mazzaferri E. L., Thyroid cancer epidemiology and prognostic variables. Clinical Oncology 2010 22 6 395 404 10.1016/j.clon.2010.05.004
2. Lukas J., Drabek J., Lukas D., The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomedical papers of the Medical Faculty of the University Palacký Olomouc, Czechoslovakia 2012 10.5507/bp.2012.086
3. Liu S., Semenciw R., Ugnat A. M., Mao Y., Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. British Journal of Cancer 2001 85 9 1335 1339 2-s2.0-0035798459 10.1054/bjoc.2001.2061 (Pubitemid 33085531)
4. Burgess J. R., Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997). Thyroid 2002 12 2 141 149 2-s2.0-0036200221 (Pubitemid 34213998)
5. Burgess J. R., Tucker P., Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 2006 16 1 47 53 2-s2.0-33644765834 10.1089/thy.2006.16.47 (Pubitemid 43346503)
6. Lubina A., Cohen O., Barchana M., Liphshiz I., Vered I., Sadetzki S., Karasik A., Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. Thyroid 2006 16 10 1033 1040 2-s2.0-33846430588 10.1089/thy.2006.16.1033 (Pubitemid 46141306)
7. Colonna M., Grosclaude P., Remontet L., Schvartz C., Mace-Lesech J., Velten M., Guizard A. V, Tretarre B., Buemi A., Arveux P., Esteve J., Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997). European Journal of Cancer 2002 38 13 1762 1768 10.1016/S0959-8049(02)00110-7
8. Leenhardt L., Grosclaude P., Chérié-Challine L., Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the french thyroid cancer committee. Thyroid 2004 14 12 1056 1060 2-s2.0-11344253462 10.1089/thy.2004.14.1056 (Pubitemid 40076130)
9. Davies L., Welch H. G., Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 18 2164 2167
10. Hundahl S. A., Fleming I. D., Fremgen A. M., A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995. Cancer 1998 83 12 2638 2648 (Pubitemid 29019586)
11. Xing M., BRAF mutation in thyroid cancer. Endocrine-Related Cancer 2005 12 2 245 262 2-s2.0-21244457181 10.1677/erc.1.0978 (Pubitemid 40896444)
12. Xing M., BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 2007 28 7 742 762 2-s2.0-37349131738 10.1210/er.2007-0007 (Pubitemid 350294294)
13. Li X., Abdel-Mageed A. B., Kandil E., BRAF mutation in papillary thyroid carcinoma. International Journal of Clinical and Experimental Medicine 2012 5 4 310 315
14. Xing M., Westra W. H., Tufano R. P., BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. The Journal of Clinical Endocrinology & Metabolism 2005 90 12 6373 6379 (Pubitemid 41759286)
15. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., Materazzi G., Elisei R., Santoro M., Miccoli P., Basolo F., Extensive clinical experience: association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 2007 92 11 4085 4090 2-s2.0-35948938528 10.1210/jc.2007-1179 (Pubitemid 350074715)
16. V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World Journal of Surgery 2012 36 2 310 317
17. Esquela-Kerscher A., Slack F. J., Oncomirs-microRNAs with a role in cancer. Nature Reviews Cancer 2006 6 4 259 269 2-s2.0-33645294070 10.1038/nrc1840
18. Pallante P., Visone R., Ferracin M., Ferraro A., Berlingieri M. T., Troncone G., Chiappetta G., Liu C. G., Santoro M., Negrini M., Croce C. M., Fusco A., MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer 2006 13 2 497 508 2-s2.0-33745077330 10.1677/erc.1.01209 (Pubitemid 43886672)
19. He H., Jazdzewski K., Li W., Liyanarachchi S., Nagy R., Volinia S., Calin G. A., Liu C.-G., Franssila K., Suster S., Kloos R. T., Croce C. M., De La Chapelle A., The role of microRNA genes in papillary thyroid carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2005 102 52 19075 19080 10.1073/pnas.0509603102 (Pubitemid 43049568)
20. Tetzlaff M. T., Liu A., Xu X., Master S. R., Baldwin D. A., Tobias J. W., Livolsi V. A., Baloch Z. W., Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocrine Pathology 2007 18 3 163 173 2-s2.0-39549094091 10.1007/s12022-007-0023-7 (Pubitemid 351384379)
21. Weber F., Teresi R. E., Broelsch C. E., Frilling A., Eng C., A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 2006 91 9 3584 3591 2-s2.0-33748752233 10.1210/jc.2006-0693 (Pubitemid 44402141)
22. Lodewijk L., Prins A. M., Kist J. W., The value of miRNA in diagnosing thyroid cancer: a systematic review. Cancer Biomark 2012 11 6 229 238
23. Xing M., Tufano R. P., Tufaro A. P., Basaria S., Ewertz M., Rosenbaum E., Byrne P. J., Wang J., Sidransky D., Ladenson P. W., Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. The Journal of Clinical Endocrinology & Metabolism 2004 89 6 2867 2872 2-s2.0-2942692120 10.1210/jc.2003-032050 (Pubitemid 38766378)
24. Livak K. J., Schmittgen T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001 25 4 402 408 2-s2.0-0035710746 10.1006/meth.2001.1262 (Pubitemid 34164012)
25. Bakhos R., Selvaggi S. M., DeJong S., Fine needle aspiration of the thyroid: rate and causes of cytopathologic discordance. Diagnostic Cytopathology 2013 23 4 233 237
26. Sung J. Y., Na D. G., Kim K. S., Diagnostic accuracy of fine-needle aspiration versus core-needle biopsy for the diagnosis of thyroid malignancy in a clinical cohort. European Radiology 2012 22 7 1564 1572
27. Nikiforova M. N., Kimura E. T., Gandhi M., Biddinger P. W., Knauf J. A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J. A., Nikiforov Y. E., BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. The Journal of Clinical Endocrinology & Metabolism 2003 88 11 5399 5404 2-s2.0-10744222003 10.1210/jc.2003-030838 (Pubitemid 37452745)
28. Namba H., Nakashima M., Hayashi T., Clinical implication of hot spot BRAF mutation V599E, in papillary thyroid cancers. The Journal of Clinical Endocrinology & Metabolism 2003 88 9 4393 4397 (Pubitemid 37153748)
29. Chou C. K., Chen R. F., Chou F. F., Chang H. W., Chen Y. J., Lee Y. F., Yang K. D., Cheng J. T., Huang C. C., Liu R. T., MiR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF V600E mutation. Thyroid 2010 20 5 489 494 2-s2.0-77952386365 10.1089/thy.2009.0027
30. Yip L., Kelly L., Shuai Y., MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma. Annals of Surgical Oncology 2011 18 7 2035 2041
31. Sheu S. Y., Grabellus F., Schwertheim S., Handke S., Worm K., Schmid K. W., Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Hormone and Metabolic Research 2009 41 6 482 487 2-s2.0-68149162638 10.1055/s-0029-1215558
32. Miller T. E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C. L., Jacob S., Majumder S., MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. The Journal of Biological Chemistry 2008 283 44 29897 29903 2-s2.0-56449092072 10.1074/jbc.M804612200
33. Yoon S. O., Chun S. M., Han E. H., Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Human Pathology 2011 42 10 1391 1400
34. Lee E. J., Gusev Y., Jiang J., Expression profiling identifies microRNA signature in pancreatic cancer. International Journal of Cancer 2007 120 5 1046 1054 (Pubitemid 46214304)
35. Visone R., Russo L., Pallante P., De Martino I., Ferraro A., Leone V., Borbone E., Petrocca F., Alder H., Croce C. M., Fusco A., MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer 2007 14 3 791 798 2-s2.0-35948975794 10.1677/ERC-07-0129 (Pubitemid 350074067)
36. Yan L. X., Huang X. F., Shao Q., Huang M. Y., Deng L., Wu Q. L., Zeng Y. X., Shao J. Y., MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008 14 11 2348 2360 2-s2.0-55549120234 10.1261/rna.1034808
37. Nakajima G., Hayashi K., Xi Y., Kudo K., Uchida K., Takasaki K., Yamamoto M., Ju J., Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics and Proteomics 2006 3 5 317 324 2-s2.0-33750726715 (Pubitemid 44701551)
38. Shi L., Cheng Z., Zhang J., Li R., Zhao P., Fu Z., You Y., hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Research 2008 1236 C 185 193 2-s2.0-53049107572 10.1016/j.brainres.2008.07.085
39. Calin G. A., Pekarsky Y., Croce C. M., The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Practice and Research in Clinical Haematology 2007 20 3 425 437 2-s2.0-34547854381 10.1016/j.beha.2007.02.003 (Pubitemid 47260321)
40. Meng F., Glaser S. S., Francis H., Functional Analysis of microRNAs in Human Hepatocellular Cancer Stem Cells. Journal of Cellular and Molecular Medicine 2012 16 1 160 173
41. Chen Y. T., Kitabayashi N., Zhou X. K., MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Modern Pathology 2008 21 9 1139 1146
42. Chou C. K., Yang K. D., Chou F. F., Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 2013 98 2 196 205